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Background: Patients with Parkinson’s disease (PD) or Parkinsonian syndromes often report 
excessive daytime sleepiness (EDS). The aim of this study was to evaluate the effects of the psy-
chostimulant modafinil on elderly, institutionalized, severely impaired PD patients with EDS.
Method: A three-week open study on ten institutionalized PD patients scoring 10 points on 
the Epworth Sleepiness Scale (ESS) with modafinil eventually on 100 mg twice a day. Patients 
were assessed at the start, week 1, and week 3 with ESS, Clinical Global Impression (CGI) 
scale severity of PD and appetite.
Results: Reduction of ESS score and PD severity over time were found as well as a significant 
increase in appetite and reduction in CGI score.
Conclusion: Modafinil 100 mg twice a day was safe and modestly effective for the treat-
ment of EDS in elderly, institutionalized PD patients. Sustaining wakefulness throughout 
all stages of PD is crucial for participating in life, maintaining social life, and improving 
quality of life.
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Background
Patients with Parkinsonian syndromes and Parkinson’s disease (PD) often report exces-
sive daytime sleepiness (EDS).1–4 This is a change in the state of consciousness with a 
difficulty to maintain wakefulness has no generally accepted definition.5 EDS can be 
identified using the Epworth Sleepiness Scale (ESS) with greater sensitivity and selec-
tivity than other tests.5 EDS commonly occurs in PD patients with prevalence figures 
ranging from 15% (versus 1%–7% in controls)1 to 51%.2 There is an estimation of a 
6% yearly increase of EDS in PD patients.3 EDS may cause reduced self esteem and 
self consciousness, impaired work performance and social interaction resulting in loss 
of independence and social isolation.6 Many patients do not have a clear awareness of 
their own sleepiness; even though EDS is often detrimental to a person’s quality of life 
(QoL). These are also the consequences with the acquainted fatigue syndrome, which 
contrasts to EDS through the lack of physical and mental energy. The EDS state can 
also be misdiagnosed with depression and memory impairment.6 Various psychiatric 
and medical health problems may also arise with EDS and even fatal accidents have 
occurred when drivers have fallen asleep at the wheel.7 The development of such a 
pathological sleepiness seems to affect especially males, cognitively impaired patients 
with advanced disease, having orthostatic hypotension or drug-induced psychosis.8 
After exclusion and treatment of any organic causes of EDS, the first step of treatment 
should be lifestyle interventions to improve the sleep pattern; this being a prerequisite Neuropsychiatric Disease and Treatment 2010:6 94
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after being screened by the ESS by a nurse and scoring 10 
points. The ESS is an 8-item questionnaire in which the 
probability to fall asleep is assessed for 8 different situations 
using a Likert scale ranging from 0 (never fall asleep) to 3 
(high risk to fall asleep) with a maximum score of 24.19 The 
cut-off score of 10 points was chosen as it is two standard 
deviations (SDs) more than the mean results for 30 normal 
controls (5.9 ± 2.2). Included were patients all having idio-
pathic PD according to the United Kingdom Parkinson’s 
Disease Society brain bank criteria20 and having a stable 
anti-PD medication dose 3 weeks prior to the study period. 
Excluded were those patients with other treatable causes 
for EDS such as: sleep apnea, rapid eye movement sleep 
behavior disorder (RBD),21 severe comorbidity or receiving 
hypnotics. Also excluded were patients with symptomatic or 
unstable cardiovascular disease, severe cognitive impairment 
(mini-mental test [MMT]  15) or receiving antipsychotic 
and antidepressant medications.
The modafinil treatment started with 100 mg in the morn-
ing for one week, followed by another 100 mg at lunch for 
another 2 weeks.
At the start, after 1 week, and 3 weeks the following tests 
were performed: ESS,19 severity of PD by Schwab & England 
(S & E),22 CGI-S (Clinical Global Impression – Severity 
scale),23 appetite score, body weight as well as side effects of 
treatment; all measurements were performed by two trained, 
independent nurses. Blood pressure and heart rate were also 
recorded; any increase of 10% was regarded as adverse side 
effects as well as new onset patients’ complaints. CGI-S con-
tains a 7-point scale requiring the observer to rate the severity 
of the patient’s illness at the time of assessment: 1 = normal,   
2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly 
ill, 6 = severely ill, or 7 = extremely ill. The patients appetite 
was measured through a visual analogue scale (VAS) ranging 
from 0 (= no appetite, eats nothing on the plate) to 10 (= very 
good appetite, eats everything on the plate).
Patients, or their relatives gave their informed consent 
to participate before the start of the study. The study was 
approved by the regional ethical committee of Karolinska 
Institute, Stockholm.
Statistics
Descriptive statistical analysis was performed to determine 
the mean, standard deviation and percentage of the baseline 
demographic variables. A generalized linear model for 
repeated analysis was performed to assess treatment effects 
at each time point and to test whether treatment interacts 
with time. ESS, S & E, CGI-S and appetite VAS were taken 
for day-time alertness. This includes no caffeine, no intake of 
fluids after 6 pm, regular bedtime, normal room temperature, 
darkness and quietness in the bedroom.9 If EDS persists 
adjustment using dopaminergic and psychotropic drugs 
should be the next step, bearing in mind the balance between 
motor deterioration and alertness. A third is the possibility 
of administering a psychostimulant drug in a low and slow 
manner, to help the patient tune up his alertness, thereby 
possibly increasing their quality of life.
Psychostimulants have a long tradition in treating cancer-
related fatigue, depression associated with malignancies and 
opioid-induced sedation. One rather new psychostimulant, 
modafinil, was approved in 1998 for the use in attention 
deficit hyperactive disorder (ADHD) and has been used to 
treat fatigue in multiple sclerosis10 and amyotrophic lateral 
sclerosis.11
Small studies with modafinil in PD patients have shown 
reduced EDS symptoms without worsening of Parkinsonian 
symptoms thereby allowing a further increase in dopami-
nergic therapy in patients previously unable to tolerate this 
because of EDS occurring as a side effect.12–14 In these studies 
modafinil was well tolerated at doses of 100–200 mg daily 
with few side-effects.13,14 However, other small studies with 
modafinil have failed to improve EDS on PD patients com-
pared to placebo.15 Moreover, recently there is also data of a 
tentative neuroprotective effect of modafinil in a marmoset 
PD model.16
The action of modafinil is on the neuronal pathways in 
the sleep/awake-centers of the brain and is target selective 
in contrast to other central nervous system (CNS)-agents 
like amphetamine and methylphenidate.17 Modafinil is read-
ily absorbed, reaching maximum plasma concentrations at   
2–4 hours post-administration, and has a half-life of   
12–15 hours. The drug is primarily metabolized in the liver. 
A steady-state is achieved within 2–4 days, with subsequent 
excretion in the urine containing less than 10% as unchanged 
drug. Patients with compromised renal or hepatic function 
may have reduced elimination. Interaction studies suggest that 
modafinil stimulates some vital liver enzymes; which requires 
attention when patients have concomitant medication.18
To our knowledge there have been no studies performed 
with modafinil on elderly, institutionalized PD patients, 
with daytime sleepiness, prompting us study the effects of 
modafinil on this type of PD patient.
Materials and methods
This study was a 3-week, single-center, open study on 
elderly (70 years), institutionalized PD patients recruited Neuropsychiatric Disease and Treatment 2010:6 95
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as dependent variables and gender was the between-subject 
  factor. The level of statistical significance was specified at 
0.05. Pairwise comparison using linear mixed model was 
made to determine if there were significant differences 
between different time points.
Results
Ten patients, five males and five females, were included in 
the study; age, gender, disease duration, height, weight and 
levodopa dose distributions are summarized in Table 1. The 
mean age was 79.7 years, the mean weight was 68.8 kg, and 
the mean levodopa dose was 506 mg.
The mean scores and standard deviations of ESS, S & E, 
CGI-S, and appetite VAS by time are displayed in Table 2. 
There was a reduction of ESS score over time (P  0.001) and 
a significant increase of S & E values over time (P = 0.011). 
A significant increase in appetite VAS score (P = 0.04) and 
a highly significant reduction in CGI-S score was observed 
(P  0.001). No time group interaction in ESS score, S & E, 
CGI-S and appetite VAS values, after initiation of treatment, 
was found. No significance between group differences was 
observed among men and women in ESS, S & E, CGI-S, and 
appetite VAS. Pairwise comparison by using linear mixed 
model indicated that there was significant difference between 
time 0 and 1 (P = 0.001) and time 0 and 3 (P  0.001).
No side effects of medication or change in weight were 
observed during the study period.
Discussion
Our data demonstrated that in this small, non-controlled 
study, 200 mg/day of modafinil was safe and modestly effec-
tive for the treatment of EDS in institutionalized, elderly PD 
patients as measured by ESS. The global assessment was 
slightly improved as well appetite. The slight increase in 
alertness, in combination with a nonspecific pharmacody-
namic effect of modafinil, might have had a positive effect 
on appetite and CGI-S. It might even be that the increased 
alertness had a general fortifying effect, as observed in the 
decreased disease severity measured by the S & E; along 
with a possible effect of modafinil on the dopaminergic 
system, thereby increasing dopamine through the inhibition 
of dopamine transporter.24 Considering the long disease dura-
tion, the mean daily levodopa dose was rather low. However, 
the therapeutic window for pharmacological PD treatment 
tends to narrow over time due to adverse side effects; often 
prompting a dose reduction.
Given our study design, sample size and concomitant 
medications, it was not possible to determine whether the 
effect of modafinil was specific on any medication-induced 
sleepiness or the EDS related to the disease itself. However, 
this was a naturalistic study trying to mimic ordinary condi-
tions in this type of patients. Another limit of this study is 
the lack of a control group, therefore the observed effect 
could be due to chance, the increased caregiver attention 
experienced by study participants or other external factors. 
However, the condition of these patients had been stable 
for several months and external conditions were kept as 
constant as possible, thereby minimizing the chance of any 
external influence affecting their condition. The use of ESS 
in elderly, institutionalized patients implies that some of 
the items of the questionnaire are not applicable to these 
patients, therefore the ESS scores must be interpreted with 
some caution. However, all patients were under the same 
conditions and in the analyses were ipsative, only comparing 
their own scores. The study design was set up with a rather 
short intervention duration due to safety reasons regarding 
these elderly, somewhat fragile patients and the possibil-
ity of any occurring side effects. However, there were no 
drug interactions or adverse side effects observed. A longer 
intervention study is warranted to determine if such positive 
Table 1 Baseline characteristics of the study population
Characteristics Mean (SD)
Age (years) 79.7 (6.1)
Disease duration (years) 15.2 (4.1)
Levodopa dose (mg) 506.0 (224.7)
Weight (kg) 68.8 (10.9)
Height (cm) 169.6 (10.7)
Male/females (n = 10) 5/5
Abbreviation: SD, standard deviation.
Table 2 Mean, standard deviation (SD), and results of the GLM 
repeated measure analysis of ESS, S & E, CGI, and appetite (VAS-
score) over time
Characteristics Mean (SD)
Baseline 1 week 3 weeks F-statistic P-value
ESS 12.7 (2.8) 11.3 (2.9) 10.6 (3.1) 15.4 0.001
S & E 42 (13.2) 46 (13.5) 47 (14.2) 6.0 0.01
CGI 5.0 (1.2) 4.4 (1.1) 4.3 (1.1) 176.2 0.001
Appetite VAS 7.9 (2.1) 8.2 (2.2) 8.3 (2.0) 5.3 0.04
Abbreviations: GLM, Generalized Linear Model; ESS, Epworth Sleepiness Scale; S & E, 
Schwab & England; CGI, Clinical Global Impression; SD, standard deviation; VAS, visual 
analogue scale.Neuropsychiatric Disease and Treatment 2010:6 96
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effects, as seen in this pilot study are sustained. It is also 
important to include a greater number of elderly patients as 
they are often only sparsely participating or being excluded 
from pharmacological clinical trials. A better understanding 
of duration and dosage is crucial to balancing benefits and 
possible risks.
The dynamics of EDS is not fully understood, although 
there seems to be a complex interaction between PD dis-
ease, dysfunction in the sleep-wake regulatory system and 
pharmacological side effects of dopaminergic drugs.25 The 
prevalence of EDS increases with age26 and they are com-
mon in PD.27 Treatment possibilities of EDS in PD depend 
upon the condition itself, as well as the individual patient, 
and include a variety of nonpharmacological processes such 
as bright light therapy and short naps at regular intervals 
during the day28 as well as scheduled activities.29 Sometimes 
wakefulness-promoting medications are necessary. Such 
medications, independent of their mode of action, are 
  prescribed to alleviate EDS. An off-label use of modafinil, 
as in this study, must have a well-founded rationale for use 
and must be undertaken, in agreement and understanding, 
with the patient and/or relatives, together with consideration 
of the cost–benefit issues. Such off-label use is a necessary 
function of the art of medicine and brings with it increased 
responsibilities for the prescriber. Liability will rest with the 
prescriber if the patient suffers adverse side effects.30 In addi-
tion, when prescribing off-label medications, the prescriber 
must make a careful risk assessment of the risks and benefits 
for the individual patients, as well as informing the patient 
that the prescription is off-label. It is noteworthy that prescrib-
ing a drug in an off-label manner is not prohibited for doctors 
and sometimes such a prescription can even constitute the 
standard care in many cases. For a long time levodopa has 
been prescribed for restless legs syndrome and during the last 
years cholinesterase inhibitors are prescribed off-label to a 
remarkable proportion of patients with vascular dementia, 
Parkinson’s disease dementia and Lewy Body dementia.31
Daytime sleepiness may cause social handicap and 
impair QoL and has long been neglected among PD issues. 
Sustaining wakefulness throughout all stages of the disease 
is crucial for participating in life and maintaining a social 
life. Thus, every measure taken to improve wakefulness 
in PD patients is of the utmost importance, especially in 
elderly patients as they often suffer from comorbidity and 
polypharmacy, both potential contributors to sleepiness. 
Therefore, in this study, we exclusively recruited elderly 
PD patients. Professional caregivers as well as relatives 
need to be observant in assessing daytime sleepiness in PD 
patients as it can impair QoL for patients and probably their 
caregivers as well.
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